ALXO Alx Oncology Holdings Inc
Price (delayed)
$0.612
Market cap
$32.67M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.58
Enterprise value
$25.01M
ALX Oncology Holdings Inc. operates as a clinical stage immuno-oncology company. The Company focuses on helping patients fight cancer by developing therapies that bridge the innate and adaptive immune system.
Highlights
The quick ratio has surged by 51% since the previous quarter and by 36% year-on-year
The EPS is up by 31% year-on-year and by 13% since the previous quarter
Alx Oncology Holdings's equity has decreased by 40% YoY and by 17% QoQ
The debt has grown by 2.7% year-on-year
Key stats
What are the main financial stats of ALXO
Market
Valuations
Earnings
Shares outstanding
53.38M
Market cap
$32.67M
Enterprise value
$25.01M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.28
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$142.47M
Net income
-$134.85M
EBIT
-$133.12M
EBITDA
-$132.25M
Free cash flow
-$122.36M
Per share
Balance sheet
Liquidity
EPS
-$2.58
EPS diluted
-$2.58
Free cash flow per share
-$2.35
Book value per share
$2.15
Revenue per share
$0
TBVPS
$2.83
Total assets
$147.78M
Total liabilities
$34.16M
Debt
$9.9M
Equity
$113.62M
Working capital
$115.85M
Debt to equity
0.09
Current ratio
7.26
Quick ratio
6.91
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-70.9%
Return on equity
-94%
Return on invested capital
-86.6%
Return on capital employed
-103%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALXO stock price
How has the Alx Oncology Holdings stock price performed over time
Intraday
-1.77%
1 week
-14.67%
1 month
-44.36%
1 year
-94.45%
YTD
-63.35%
QTD
-1.77%
Financial performance
How have Alx Oncology Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$142.47M
Net income
-$134.85M
Gross margin
N/A
Net margin
N/A
ALXO's net income is up by 16% year-on-year and by 11% since the previous quarter
ALXO's operating income is up by 16% YoY and by 11% QoQ
Growth
What is Alx Oncology Holdings's growth rate over time
Valuation
What is Alx Oncology Holdings stock price valuation
P/E
N/A
P/B
0.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 31% year-on-year and by 13% since the previous quarter
The price to book (P/B) is 91% less than the 5-year quarterly average of 3.1 and 83% less than the last 4 quarters average of 1.7
Alx Oncology Holdings's equity has decreased by 40% YoY and by 17% QoQ
Efficiency
How efficient is Alx Oncology Holdings business performance
ALXO's return on equity is down by 19% year-on-year
The return on assets has declined by 9% year-on-year
ALXO's return on invested capital is down by 4.8% year-on-year
Dividends
What is ALXO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALXO.
Financial health
How did Alx Oncology Holdings financials performed over time
Alx Oncology Holdings's current ratio has soared by 51% from the previous quarter and by 39% YoY
The quick ratio has surged by 51% since the previous quarter and by 36% year-on-year
The debt is 91% smaller than the equity
Alx Oncology Holdings's debt to equity has soared by 80% YoY and by 29% from the previous quarter
Alx Oncology Holdings's equity has decreased by 40% YoY and by 17% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.